Literature DB >> 28106536

The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.

Samir F Zohny1,2, Othman A Baothman1, Mohamed El-Shinawi3, Abdulrahman L Al-Malki1, Mazin A Zamzami1, Hani Choudhry1.   

Abstract

OBJECTIVE: We examined the expression status of p21^{Waf1/Cip1} and p57^{Kip2} in breast cancer as well as their relationship with clinicopathological factors. Moreover, the diagnostic value of gene promoter methylation of p21^Waf1/Cip1 and p57^Kip2 was assessed in breast cancer patients.
METHODS: This study involved 85 patients diagnosed with breast cancer and 36 patients with benign breast lesions. The expression of p21^{Waf1/Cip1} and p57^{Kip2} in cell lysates was analyzed by ELISA and Western blot, respectively. The gene promoter methylation of p21^Waf1/Cip1 and p57^Kip2 was examined in cell lysates by methylation specific PCR.
RESULTS: p21^{Waf1/Cip1} expression was higher while p57^{Kip2} level was lower in breast cancer patients compared to patients with benign breast lesions. The combined use of p21^{Waf1/Cip1} and p57^{Kip2} provided sensitivity and specificity of 82.35% and 86.11%, respectively. None of the malignant and benign breast tumors were found to be hypermethylated at p21^Waf1/Cip1 gene promoter. However, aberrant methylation of p57^Kip2 gene promoter was detected in 49 of 85 (57.65%) of breast cancer tumors. High p21^{Waf1/Cip1} level was associated with high grade, late stages and lymph node involvement, whereas low p57^{Kip2} level was correlated with high grade and HER2 overexpressing breast cancer. Moreover, hypermethylated p57^Kip2 gene promoter was associated with high grade.
CONCLUSION: Our findings show that the overexpression of p21^{Waf1/Cip1}, down-expression of p57^{Kip2} and gene promoter methylation of p57^Kip2 could be considered as promising diagnostic markers for breast cancer.

Entities:  

Keywords:  Breast cancer; clinicopathological factors; gene promoter methylation; p21^{Waf1/Cip1}; p57^{Kip2}

Mesh:

Substances:

Year:  2017        PMID: 28106536     DOI: 10.3233/CBM-160308

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer.

Authors:  Vincent T Wu; Boris Kiriazov; Kelsey E Koch; Vivian W Gu; Anna C Beck; Nicholas Borcherding; Tiandao Li; Peter Addo; Zachary J Wehrspan; Weizhou Zhang; Terry A Braun; Bartley J Brown; Vimla Band; Hamid Band; Mikhail V Kulak; Ronald J Weigel
Journal:  Mol Cancer Res       Date:  2019-10-16       Impact factor: 5.852

2.  Concomitance of downregulated active caspase-3 and upregulated X-chromosome linked inhibitor of apoptosis protein as a sensitive diagnostic approach for breast cancer.

Authors:  Samir F Zohny; Mazin A Zamzami; Mohamed El-Shinawi
Journal:  Mol Cell Biochem       Date:  2018-11-16       Impact factor: 3.396

3.  Effect of Ionizing Radiation on the Transcript Variants Expression of p21 Gene.

Authors:  Amir Danyaei; Ali Teimoori; Hashem Khanbabaei; Halime Mansoury Asl
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

4.  Investigation of the Effect of Zebularine in Comparison to and in Combination with Trichostatin A on p21Cip1/Waf1/ Sdi1, p27Kip1, p57Kip2, DNA Methyltransferases and Histone Deacetylases in Colon Cancer LS 180 Cell Line.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

Review 5.  Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.

Authors:  Emanuela Stampone; Ilaria Caldarelli; Alberto Zullo; Debora Bencivenga; Francesco Paolo Mancini; Fulvio Della Ragione; Adriana Borriello
Journal:  Int J Mol Sci       Date:  2018-04-02       Impact factor: 5.923

Review 6.  Significant function and research progress of biomarkers in gastric cancer.

Authors:  Dong Mei Ye; Gaosheng Xu; Wei Ma; Yuxuan Li; Weiru Luo; Yiyang Xiao; Yong Liu; Zhiwei Zhang
Journal:  Oncol Lett       Date:  2019-11-11       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.